In this inspiring interview, Chandler Harris shares his journey of faith, healing, and everyday ministry through spontaneous acts of love and prayer. Discover how simple acts like praying for Uber drivers and grocery store workers can transform lives and deepen your spiritual walk.Chapters00:00 Introduction to Breakthrough Church and Family Background01:51 Personal Testimonies and Healing Experiences12:00 Everyday Mission: Praying for Uber Drivers20:05 Engaging Conversations in Everyday Life28:07 The Impact of Community and Spiritual Growth

In this episode of "In the Interim…" Dr. Scott Berry is joined by Professors Victoria Cornelius, Danny McAuley, and Anthony Gordon, for a technical review of the PANTHER trial—an international, Phase 2 adaptive platform evaluating pharmacologic interventions for ARDS. The trial is open-label and does not employ blinding, as discussed in the episode. The primary endpoint is 28-day organ support-free days (death as -1, survivors 0–28 days), analyzed with a Bayesian proportional odds model. PANTHER uses  stratification by hyper- and hypoinflammatory subphenotypes, with fixed, equal randomization within each stratum. Analyses for treatments are separated by stratum, reflecting the potential of differential treatment effects. Quarterly interim analyses allow early stopping by stratum for efficacy or futility. Content includes explicit discussion of infrastructure: rapid device deployment, centralized data for trial and future biological discovery, and governance challenges in multinational collaboration. Funding is provided by NIHR (UK), US Department of Defense, CIHR (Canada), NHMRC and MRFF (Australia), HRB (Ireland), and additional support from Germany and Japan. PANTHER is positioned to streamline Phase 2 critical care drug testing and facilitate graduation to larger platforms such as REMAP-CAP, with potential to expedite pharmaceutical evaluation and accelerate ARDS therapeutic development.Key HighlightsReal-time phenotyping (Randox device) to stratify ARDS patients.Separate Bayesian analyses by phenotype stratum.Open-label, fixed randomization within stratum.28-day organ support-free days as a composite endpoint.Quarterly interim analyses enable early dropping or graduation of arms by strata.Central data resource and biosample collection for future research.Operational, funding, and device logistics for global trial deployment.Transition of Phase 2 results to established Phase 3 platforms (e.g., REMAP-CAP).For more, visit us at https://www.berryconsultants.com/

In this episode of AWM Insights, Chief Investment Officer Justin Dyer and Portfolio Manager Mena Hanna break down the latest market movements in the wake of a global ceasefire and explore what it means for long-term investors. The discussion covers the efficiency of markets, the distinction between investing and gambling, and why discipline is more rewarding than chasing headlines. Whether you're managing generational wealth or simply curious about how to weather market volatility, this episode delivers clear, seasoned guidance to help you play the long game with confidence.Chapters(00:00) Market Reactions to Ceasefire(01:08) Efficiency and Interpretation of Markets(03:58) Short-Term Versus Long-Term Market Behavior(05:25) The Importance of Discipline and Long-Term Focus(07:17) Navigating Volatility and Uncertainty(09:01) Oil Market Impacts and Inflation OutlookConnect with Us• Call or text us: 626-862-0355• Website: https://www.athletefamilyoffice.com/• YouTube: https://www.youtube.com/channel/UCc1NxpK21N1vKWEExC45YEA• LinkedIn: https://www.linkedin.com/company/awmcapital/• Instagram: https://www.instagram.com/awmcapital/• X: https://twitter.com/awmcapital• Facebook: https://www.facebook.com/awmcapital/

This episode shares a personal journey of spiritual renewal, healing, and faith in action. The host discusses recent inner healing, the power of the gospel, and practical ways to live out faith through healing and evangelism.Chapters00:00 Celebrating New Beginnings02:54 Inner Healing and Deliverance06:12 Preaching with Freedom08:59 Expecting Signs and Wonders11:49 Transitioning to Galatians15:13 Living by Faith18:06 Mobilizing the Gospel20:56 Sharing Your Testimony

In this episode of "In the Interim…", Dr. Scott Berry connects with Dr. Byron Gajewski, professor of biostatistics and data science at the University of Kansas Medical Center (KUMC), for a detailed discussion on the design, simulation, and operational realities of Bayesian adaptive clinical trials in academic environments. Gajewski discusses his academic background, training at Texas A&M, and progressive adoption of Bayesian principles based on direct experiential advantages in complex data settings. The conversation highlights KUMC’s Fixed and Adaptive Clinical Trial Simulator Working Group, which utilizes FACTS for faculty, staff, and student collaboration, enabling practical simulation, trial protocol development, and in-house applied statistical training. The PAIN-CONTRoLS Trial serves as a practical example of multi-arm Bayesian adaptive design, using response-adaptive randomization for comparative effectiveness in neuropathy research. The NIH-funded HOBIT trial is examined in detail: multi-arm structure, adaptive allocation among investigational arms, fixed control randomization, group-sequential interim analyses, and sliding dichotomy methodology for the Glasgow Outcome Scale Extended. The discussion stresses a shift to probabilistic, evidence-driven interpretation and reporting, shaping operational choices and academic culture for both investigators and trainees.Key HighlightsGajewski describes how practical challenges in real-world problems catalyzed his transition to Bayesian modeling.KUMC’s working group integrates FACTS software in collaborative simulation and operational trial planning.The PAIN-CONTRoLS Trial: multi-arm Bayesian adaptive design, response-adaptive randomization, real-time analysis, and endpoint-driven allocation.HOBIT trial: Adaptive allocation, fixed control arm proportion, group-sequential interims, ordinal endpoint modeling.Emphasis on probabilistic, quantitative reporting over binary outcomes in trial analysis and interpretation.Cultural shift observed among academic collaborators and trainees embracing Bayesian adaptive strategies.